Mesoblast Limited (MEOBF)
OTHER OTC:MEOBF
MEOBF Stock Chart & Stats
$1.60
$0.00(0.00%)
At close: 4:00 PM EST
$1.60
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.96 - $2.59
Previous CloseN/A
Volume20.00
Average Volume (3M)69.00
Market Cap
$1.83B
Enterprise Value$1.84B
Total Cash (Recent Filing)$161.16M
Total Debt (Recent Filing)$128.16M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Sep 02, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,291,562,700
10 Day Avg. Volume100
30 Day Avg. Volume69
Financial Highlights & Ratios
PEG Ratio-27.18
Price to Book (P/B)2.09
Price to Sales (P/S)72.48
P/FCF Ratio-24.59
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue106.78
Enterprise Value/Gross Profit-51.21
Enterprise Value/Ebitda-31.56
Forecast
1Y Price Target
$2.46Price Target Upside53.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$89.37M
Bulls Say, Bears Say
Bulls Say
Commercial Launch & RevenueA successful commercial launch with USD 49M in H1 demonstrates validated customer demand, payer acceptance and an initial sustainable revenue base. Durable commercialization capability and early adoption create a foundation for scaling sales, recurring product revenues and long-term market penetration if execution continues.
Very High Gross MarginsIndustry-leading gross margins (93%) indicate highly favorable product economics and significant operating leverage potential. Durable high margins support future profitability as volumes grow, enable reinvestment in R&D/commercial expansion, and provide buffer against pricing or reimbursement pressure if manufacturing scale and quality are maintained.
Balance Sheet & FinancingA solid cash position plus a large nondilutive credit facility gives multi-month runway to fund commercialization, trials and regulatory filings. Low leverage and optional tranche availability reduce immediate refinancing risk and provide strategic flexibility to execute filings and scale operations over the next 2–6 months.
Bears Say
Revenue ConcentrationNear-term revenue is heavily reliant on a single product, leaving the company exposed to demand swings, payer policy shifts, or manufacturing disruptions. Durable revenue diversification is still pending and concentration increases operating risk if launch momentum stalls or competitive/regulatory hurdles arise.
Negative Operating Cash FlowPersistent negative operating cash flow, despite improving free cash flow metrics, means the business continues to rely on financing to fund operations. This structural cash burn constrains flexibility, makes results sensitive to drawing credit tranches, and elevates execution risk until operating cash flow turns sustainably positive.
Rising R&D And SG&A SpendMaterial increases in R&D and SG&A reflect necessary investment into trials, filings and commercial rollout, but also raise the structural cost base. If revenue growth or regulatory approvals lag, elevated recurring expenses will pressure margins and cash, making sustained profitability and self-funded growth harder to attain.
Mesoblast Limited News
MEOBF FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest stock price was $0.96 and its highest was $2.59 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is $1.83B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is Sep 02, 2026 which is in 146 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -$0.031 earnings per share for the quarter, missing the consensus estimate of -$0.007 by -$0.024.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is 0.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,291,562,700 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -$0.031 in its last earnings report, missing expectations of -$0.007. Following the earnings report the stock price went down -2.516%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in MEOBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.46 (53.62% Upside)
$2.46 (53.62% Upside)
Blogger Sentiment
Bullish
MEOBF Sentiment 98%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $15.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.82%
12-Months-Change
Fundamentals
Return on Equity
-14.02%
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MEOBF Company Deck
MEOBF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum from the Ryoncil launch (USD 49M H1 revenue), industry-leading gross margins (93%), broad payer coverage, rapid center onboarding and multiple near-term regulatory and clinical milestones (Revascor BLA next quarter; back pain enrollment completion and 2027 BLA). The company also strengthened its balance sheet with USD 130M cash and a USD 125M credit facility. Offsetting risks include a sharp increase in R&D and SG&A spending, reliance on Ryoncil for most revenues, ongoing manufacturing/CMC items ahead of filings, and near-term cash usage (USD 30.3M H1) with a tranche deadline in June 2026. Overall, the positive operational, clinical and financial developments materially outweigh the execution and expense risks.View all MEOBF earnings summariesMEOBF Stock 12 Month Forecast
Average Price Target
$2.46
▲(53.62% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Ownership Overview
22.10% Insiders
2.29% Mutual Funds
0.01% Other Institutional Investors
72.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---